^
Association details:
| Biomarker: | KRAS mutation + CDK9 overexpression + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
335P - Resistance to CDK4/6 inhibitors: Clinical practice use of liquid biopsy to identify KRAS-mutations in ctDNA and overexpression of CDK9 in plasma derived exosomes
Published date:
09/14/2020
Excerpt:
At 18-month follow up [1-NA], pts with KRAS-mutated ctDNAand overexpression of CDK9 had a median PFS of 3 months [1-6months,95%CI 0.8-3.6] contrary to ones with no detection of KRAS ctDNA whose PFS had not yet been reached (p<0.001).
